Alzheimers Disease
New Alzheimer’s Disease research breakthroughs
New treatment options are unlocking hope for millions of adults and loved ones affected by Alzheimer's
Alzheimer’s Disease was first discovered in the early 1900s by a German doctor, Alois Alzheimer, who had the occasion to examine brain matter of a patient who had passed away after exhibiting memory loss and behavioral challenges. Over the past 100+ years since, Alzheimer’s dementia has come to affect more than 5.5 million Americans, robbing them of precious memories and severely limiting quality of life during what should be the “golden years.”
With such devastating impact on so many as they age, Alzheimer’s Disease has commanded significant attention by way of clinical research. In the 1980s it was discovered that Alzheimer’s is caused by a build-up of plaque called beta-amyloid in the brain. This plaque can disrupt normal cell functioning and lead to the symptoms exhibited by Alzheimer’s dementia – memory loss along with increasing confusion and lack of self-care ability.
In the last few years alone, hundreds of clinical trials focused on the disease have been undertaken to better understand the root cause of the condition and to help limit or stall its effects. Until 2021, only two classes of drugs had been approved by the FDA to aid patients suffering with Alzheimer’s: cholinesterase inhibitors such as Aricept that can potentially ease symptoms at any stage, and a receptor antagonist, Memantine, to slow progression in those that are in an early disease state.
The 2020s however have seen more positive activity on the Alzheimer’s front than in any other previous decade. Recently a handful of clinical trials have reported positive results on the Alzheimer’s disease landscape with two trials leading to fairly rapid FDA approvals. First out of the gate was Aduhelm, a monoclonal antibody approved in 2021 after demonstrating reduced brain plaque in patients with mild disease. The drug is delivered via a monthly infusion to help slow cognitive decline in people at the early stages of onset.
Shortly after Aduhelm was announced, the FDA issued another accelerated approval for a different monoclonal antibody demonstrated to also clear the presence of amyloid plaque in the brain. Leqembi, like Aduhelm, is given to patients with mild cognitive impairment via an intravenous infusion. In a research study with 1,800 participants diagnosed with early-stage disease, the therapy helped reduce decline in thinking by 27 percent over an 18-month period.
In 2023, a report stemming from a clinical trial of yet another monoclonal antibody, donanemab, was released showing even more promising results. In a study of 1,700 participants, more than one-third experienced slower mental decline when compared with participants on placebo. In addition, 47 percent of participants in the trial assigned to the therapy experienced stable disease, meaning that their disease that did not worsen, over the course of the trial. The drug was approved by the FDA in July 2024 for treatment in patients with early, symptomatic disease.
With any treatment, there are risks and benefits to be weighed based on the whole-health picture of a patient. But for Alzheimer’s patients and their loved ones, recent progress such as that reported with new monoclonal antibody therapies shown to help remove amyloid plaque are providing much needed glimmers of hope.
Keep up to date on the latest research
Interested in learning more about Alzheimer’s disease? Register here on ClinicalResearch.com to receive news about Alzheimer's disease and related clinical trials. Check back often for updates and news on a variety of disease areas and to find out more about some of the latest clinical research trials.
With such devastating impact on so many as they age, Alzheimer’s Disease has commanded significant attention by way of clinical research. In the 1980s it was discovered that Alzheimer’s is caused by a build-up of plaque called beta-amyloid in the brain. This plaque can disrupt normal cell functioning and lead to the symptoms exhibited by Alzheimer’s dementia – memory loss along with increasing confusion and lack of self-care ability.
In the last few years alone, hundreds of clinical trials focused on the disease have been undertaken to better understand the root cause of the condition and to help limit or stall its effects. Until 2021, only two classes of drugs had been approved by the FDA to aid patients suffering with Alzheimer’s: cholinesterase inhibitors such as Aricept that can potentially ease symptoms at any stage, and a receptor antagonist, Memantine, to slow progression in those that are in an early disease state.
The 2020s however have seen more positive activity on the Alzheimer’s front than in any other previous decade. Recently a handful of clinical trials have reported positive results on the Alzheimer’s disease landscape with two trials leading to fairly rapid FDA approvals. First out of the gate was Aduhelm, a monoclonal antibody approved in 2021 after demonstrating reduced brain plaque in patients with mild disease. The drug is delivered via a monthly infusion to help slow cognitive decline in people at the early stages of onset.
Shortly after Aduhelm was announced, the FDA issued another accelerated approval for a different monoclonal antibody demonstrated to also clear the presence of amyloid plaque in the brain. Leqembi, like Aduhelm, is given to patients with mild cognitive impairment via an intravenous infusion. In a research study with 1,800 participants diagnosed with early-stage disease, the therapy helped reduce decline in thinking by 27 percent over an 18-month period.
In 2023, a report stemming from a clinical trial of yet another monoclonal antibody, donanemab, was released showing even more promising results. In a study of 1,700 participants, more than one-third experienced slower mental decline when compared with participants on placebo. In addition, 47 percent of participants in the trial assigned to the therapy experienced stable disease, meaning that their disease that did not worsen, over the course of the trial. The drug was approved by the FDA in July 2024 for treatment in patients with early, symptomatic disease.
With any treatment, there are risks and benefits to be weighed based on the whole-health picture of a patient. But for Alzheimer’s patients and their loved ones, recent progress such as that reported with new monoclonal antibody therapies shown to help remove amyloid plaque are providing much needed glimmers of hope.
Keep up to date on the latest research
Interested in learning more about Alzheimer’s disease? Register here on ClinicalResearch.com to receive news about Alzheimer's disease and related clinical trials. Check back often for updates and news on a variety of disease areas and to find out more about some of the latest clinical research trials.
Published Date May 02, 2024
Latest News
Diabetes
Participating in clinical research from your home
A DCT brings cutting-edge research fueled by digital innovation straight into a person's home for utmost convenience
2025-08-05T17:23:00Z
Non-Hodgkin Lymphoma
The ABCs of blood cells and blood cancers: Lymphoma
Every blood cell has an important job to do but sometimes cancer gets in the way
2025-06-13T17:22:00Z
Non-Hodgkin Lymphoma
How dogs are helping advance lymphoma research
Dogs are furry and faithful companions that too can face cancer - learn how some are benefiting from medical research
2025-05-28T17:36:00Z
Melanoma
Melanoma: Separating Myths from Facts
Melanoma is a serious form of cancer yet many myths persist around what it is, where it is, and who is at risk
2025-04-28T21:05:00Z
Melanoma
Advances in Melanoma Treatment
Clinical research is helping bring new, and much-needed, treatments to market
2025-04-15T21:17:00Z
Asthma
New thinking in childhood asthma diagnosis approach
New studies show that over-calculating race risk in asthma diagnostic tools may actually delay diagnosis
2025-03-21T13:51:00Z
Alzheimer's Disease
As America ages, dementia diagnoses poised to double
With humans living longer due to medical breakthroughs, the chance of developing dementia has greatly increased
2025-02-19T13:56:00Z
Multiple Sclerosis (MS)
Is lassitude affecting your attitude?
The extreme fatigue of MS is so unrelenting that it has its own name: lassitude. What can you do to try and improve this feeling?
2025-01-24T18:58:00Z
Asthma
Breathing easy: the work of an asthma inhaler
Inhalers are lifechanging for people living with asthma and other breathing difficulties
2025-01-07T17:33:00Z
Leukemia (AML)
A simple guide to understanding chemo
Chemo is an effective cancer treatment - but what is it exactly and why does it work?
2024-12-09T14:25:00Z
Eczema
Self-care tips during eczema flare-ups
Eczema can be emotionally draining and physically uncomfortable - learn how self-care can change your outlook
2024-11-26T18:46:00Z
Healthy Volunteers
What is a Phase 1 trial?
Phase 1 trials are necessary first steps on the road to clinical breakthroughs and healthy volunteers can help make these a reality.
2024-11-11T15:35:00Z
Colorectal Cancer
The role of biomarker testing in cancer
Biomarkers can play important roles in cancer treatment, but what are they and what can they tell doctors?
2024-10-16T18:18:00Z
Hypertension
Home-based exercise tips for blood pressure control
Getting heart-healthy physical activity doesn't have to mean running a marathon or joining an expensive gym.
2024-09-08T18:30:00Z
Leukemia (AML)
What helps with nausea besides medicine?
Nausea is an unfortunate aspect of cancer treatment - what may help reduce this side effect?
2024-08-31T18:30:00Z
Healthy Volunteers
Common misconceptions about clinical research
Many people have never participated in a clinical trial so it can be hard to separate fact from myth - here are some of the most common myths debunked.
2024-08-28T21:23:00Z
Obesity
The basics of BMI
BMI, or Body Mass Index, is a standard way to assess weight status - learn why and where it came from
2024-08-22T13:50:00Z
Colorectal Cancer
Why is Colorectal Cancer striking at younger ages?
The number of people being diagnosed with colorectal cancer under the age of 50 has greatly increased - what might be the cause of this troubling trend?
2024-08-14T16:12:00Z
Hypertension
Four foods linked with lower blood pressure
While the foods you eat can raise the risk of developing hypertension, there are also options that can help lower blood pressure.
2024-08-01T18:30:00Z
Obesity
A primer on GLP-1 receptor agonists for weight loss
An overview on select GLP-1 receptor agonist treatments that help promote blood sugar management and weight loss
2024-07-31T18:30:00Z
Multiple Myeloma
Life with a rare disease
Experiencing serious health challenges is difficult enough - having a relatively unknown condition adds additional complexity
2024-07-08T22:02:00Z
Eczema
Atopic Dermatitis: signs and stages
Understanding how atopic dermatitis looks, feels and changes during a flare-up is helpful to patients seeking greater control of their condition
2024-07-01T16:12:00Z
Metabolic dysfunction-associated steatohepatitis (MASH)
Speaking with your PCP about MASH
Engaging your primary doctor in a conversation about risk for MASH liver disease doesn't have to be scary
2024-06-25T12:15:00Z
Alzheimer's Disease
New Alzheimer’s Disease research breakthroughs
The 2020s have been the most impactful decade so far for the debilitating form of dementia
2024-05-02T18:30:00Z
Breast Cancer
Talking to family about cancer genes
Though this conversation may be difficult, it might be vitally important for your loved ones
2024-02-05T18:30:00Z
Lupus
Lupus (Systemic Lupus Erythematosus) and Diet
Can what you eat make a difference?
2024-04-15T18:30:00Z
Metabolic dysfunction-associated steatohepatitis (MASH)
Learning you need a liver biopsy: staying calm
Approaches to stay in control before, during and after a biopsy
2023-12-27T18:30:00Z
Diabetes
The recent rise of walking as exercise
Grab your sneakers, grab a friend, or grab your dog and get moving!
2023-12-05T18:30:00Z
Renal Cell Carcinoma
Coping with the holidays during cancer treatment
Getting ready to face a new year while facing cancer is no easy task
2023-11-23T18:30:00Z
Multiple Sclerosis (MS)
Possible link between multiple sclerosis and viral infection?
Researchers are looking to learn more about if and how a virus can trigger multiple sclerosis
2023-10-25T18:30:00Z
Metabolic dysfunction-associated steatohepatitis (MASH)
Making lifestyle changes: ten ideas to get started
Losing excess weight together with an active lifestyle helps with the management of MASH, but where to begin?
2023-09-05T18:30:00Z
Lung Cancer
Talking to loved ones about your clinical trial
How to talk to family and friends when you are thinking of changing cancer treatment plans for a research option
2023-08-14T18:30:00Z
Lung Cancer
Learning you have lung cancer as a non-smoker
Lung cancer can be a shocking diagnosis when you've never smoked - how can it be?
2023-08-15T18:30:00Z
Prostate Cancer
Does a high PSA score always mean cancer?
Learn more about this common test for older men and how it relates to cancer risk
2023-07-10T18:30:00Z
Breast Cancer
Understanding the differences between mastectomy and lumpectomy
Two different surgical options both seeking the same outcome
2023-07-07T18:30:00Z
Lupus
New treatments are on the horizon for lupus patients
From biologics to CAR-T, developments in clinical research for SLE have opened new treatment doors for patients.
2023-05-22T16:15:00Z
Multiple Myeloma
Understanding eligibility criteria for clinical research studies
Clinical trials utilize sets of criteria to determine if a person is a good fit - but what are these and what do they mean?
2023-04-05T18:30:00Z
Renal Cell Carcinoma
Learning you need a biopsy: staying calm
Approaches to stay in control before, during and after a diagnostic biopsy
2023-03-14T18:30:00Z
Metabolic dysfunction-associated steatohepatitis (MASH)
Making lifestyle changes: ten ideas to get started
Pharmaceutical companies are rushing to fill the NASH treatment gap
2023-03-14T18:30:00Z